ZURICH (Reuters) - Novartis AG said on Monday its drug Gilenya failed to meet its main goal in a late-stage study as a treatment for primary progressive multiple sclerosis (PPMS). Results of the Phase III trial involving 970 people found Gilenya, also known as fingolimod, did not show a significant difference to placebo on a combination of disability measures. There are currently no approved treatments for PPMS, a disorder of the central nervous system characterized by a steady worsening of neurologic functioning over time. It affects around 10 percent of the 2. ...
via Health News Headlines - Yahoo News http://ift.tt/1y79BGV
No comments:
Post a Comment